Piper Sandler Maintains Overweight on AtriCure, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on AtriCure (NASDAQ:ATRC) but lowers the price target from $65 to $40.
July 31, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Piper Sandler analyst Matt O'Brien maintains an Overweight rating on AtriCure but lowers the price target from $65 to $40.
The lowered price target from $65 to $40 suggests a less optimistic outlook for AtriCure's stock performance, which could lead to a short-term decline in its stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100